The City of Baltimore has filed a lawsuit against multiple kratom manufacturers and distributors, according to court documents, alleging deceptive marketing practices and the sale of dangerous, unregulated herbal substances to consumers. The legal action targets companies operating within the booming botanical supplement market, focusing on allegations that they downplay the addictive nature and health risks of kratom while marketing the products as safe alternatives to opioids or pain relievers.
Kratom, derived from the tropical tree Mitragyna speciosa native to Southeast Asia, acts on opioid receptors in the brain. According to the U.S. Food and Drug Administration (FDA), the substance carries risks of abuse, dependence, and addiction. Despite federal warnings and a current import alert, kratom remains largely unregulated at the federal level, leaving state and local municipalities to pursue legal remedies against manufacturers over consumer protection violations and public nuisance claims.
Allegations of Deceptive Marketing Practices
According to the complaint filed by the Baltimore City Solicitor’s Office, the defendant manufacturers utilized aggressive and misleading marketing campaigns to convince vulnerable populations that kratom is entirely safe and natural. The lawsuit asserts that these companies failed to provide adequate warning labels regarding the potential for addiction, liver damage, and overdose, violating state consumer protection laws.
City officials argue that these marketing strategies specifically targeted individuals seeking relief from chronic pain or substance use disorders, falsely portraying the botanical supplement as a benign wellness product. Public health advocates and municipal leaders point to a rising number of emergency room visits and calls to poison control centers associated with kratom use as the primary driver behind the enforcement action.
Regulatory Landscape and Public Health Concerns
The legal battle in Baltimore highlights a broader national debate over the regulation of herbal supplements. While several U.S. states have enacted total bans on kratom sales—including Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin—other jurisdictions permit sales with varying age restrictions or labeling requirements. The FDA has repeatedly warned consumers not to use kratom, citing a lack of comprehensive safety data and numerous reports of adverse health effects, including deaths linked to adulterated products.
Industry trade groups, such as the American Kratom Association, frequently argue that responsible vendors offer high-quality, lab-tested products that serve as a valuable alternative for adult consumers. However, local governments are increasingly turning to civil litigation to curb marketing tactics they deem predatory, mirroring strategies previously employed against tobacco and opioid manufacturers.
Next Steps in the Litigation
The lawsuit will proceed through the Baltimore City Circuit Court, where the defendants will have the opportunity to respond to the city’s claims. Legal analysts expect the proceedings to center on whether the manufacturers’ marketing claims crossed the line from protected commercial speech into unlawful deceptive trade practices. A scheduling order for initial hearings is expected in the coming weeks as both parties exchange preliminary discovery requests.